Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. 1990

H Yoshida, and M Nakamura, and M Bogaki, and S Nakamura
Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Osaka, Japan.

The proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa was examined by introducing the cloned wild-type Escherichia coli gyrA and gyrB genes. Of 101 spontaneous mutants of P. aeruginosa PAO505, 33 (33%) were found to have gyrA mutations. Among 17 clinical isolates, 12 (71%) had gyrA mutations and 1 (6%) had a gyrB mutation.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D014170 Transformation, Genetic Change brought about to an organisms genetic composition by unidirectional transfer (TRANSFECTION; TRANSDUCTION, GENETIC; CONJUGATION, GENETIC, etc.) and incorporation of foreign DNA into prokaryotic or eukaryotic cells by recombination of part or all of that DNA into the cell's genome. Genetic Transformation,Genetic Transformations,Transformations, Genetic
D042462 4-Quinolones QUINOLONES containing a 4-oxo (a carbonyl in the para position to the nitrogen). They inhibit the A subunit of DNA GYRASE and are used as antimicrobials. Second generation 4-quinolones are also substituted with a 1-piperazinyl group at the 7-position and a fluorine at the 6-position. 4-Oxoquinoline,4-Quinolinone,4-Quinolone,4-Oxoquinolines,4-Quinolinones,4 Oxoquinoline,4 Oxoquinolines,4 Quinolinone,4 Quinolinones,4 Quinolone,4 Quinolones

Related Publications

H Yoshida, and M Nakamura, and M Bogaki, and S Nakamura
September 1995, Antimicrobial agents and chemotherapy,
H Yoshida, and M Nakamura, and M Bogaki, and S Nakamura
October 2017, The Journal of antimicrobial chemotherapy,
H Yoshida, and M Nakamura, and M Bogaki, and S Nakamura
September 1994, Antimicrobial agents and chemotherapy,
H Yoshida, and M Nakamura, and M Bogaki, and S Nakamura
January 2018, 3 Biotech,
H Yoshida, and M Nakamura, and M Bogaki, and S Nakamura
January 1983, Biochemical and biophysical research communications,
H Yoshida, and M Nakamura, and M Bogaki, and S Nakamura
September 1991, The Journal of antimicrobial chemotherapy,
H Yoshida, and M Nakamura, and M Bogaki, and S Nakamura
July 1998, Biological & pharmaceutical bulletin,
H Yoshida, and M Nakamura, and M Bogaki, and S Nakamura
September 1998, Antimicrobial agents and chemotherapy,
H Yoshida, and M Nakamura, and M Bogaki, and S Nakamura
January 1998, Microbial drug resistance (Larchmont, N.Y.),
Copied contents to your clipboard!